As we have reached the end of April, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly/monthly moves and YTD moves
All BPIQ Companies
Gene Editing Companies
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week of 4/25-4/29
Biggest positive move
$NKTX +140.9% Announced positive data then issued an offering.
Biggest negative move
$ELYM -55.8% Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs - ETX-810 Ph 2a failed and delayed enrollment in ETX-155 ph 2a.
Additional big moves
$PTGX -39.4% Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
$ARDX +31.8% Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor).
$AVDL -36.0% Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting.
$VERU +25.8% Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases.
$PRTA -14% Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.
$AVDL +26% Avadel Pharmaceuticals Provides Comment on Recent Trading Activity.
$ERYP -23% Disposition of certain assets and inventory to Catalent.
$SLDB -17.0% Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy source
$FNCH +33.8% Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND source
$ZYME +33.1% Zymeworks Reports Last Patient Enrolled In Pivotal Study Of Zanidatamab In Treatment Of HER2-Expressing Late-Line Biliary Tract Cancer source
$GNCA -24.1% Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives source
Highlights for next week
Keep an eye out for upcoming updates on ASCO
PDUFA target action dates: $SUPN, $HCM, $CHRS, and $AXSM